SANTA CRUZ BIOTECHNOLOGY, INC.

DRG2 (L-13): sc-164233

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

DRG2 (developmentally regulated GTP binding protein 2) is a 364 amino acid cytoplasmic protein involved in cell proliferation, differentiation and death. A member of the DRG subfamily of the GTP-binding protein superfamily, DRG2 is highly expressed in kidney, heart and skeletal muscle, with low levels found in thymus, colon, spleen, lung, small intestine and leukocytes. DRG2 undergoes post-translational polyubiquitination, leading to proteolytic degradation. DRG2 interacts with RWDD1 (RWD domain containing 1), and is encoded by a gene that is located in a region on human chromosome 17 associated with Smith-Magenis syndrome (SMS). SMS is a disorder characterized by multiple congenital anomalies, abnormal sleep patterns, maladaptive repetitive and self-injurious actions and behavior problems.

REFERENCES

1. Schenker, T., Lach, C., Kessler, B., Calderara, S. and Trueb, B. 1994. A novel GTP-binding protein which is selectively repressed in SV40 transformed fibroblasts. J. Biol. Chem. 269: 25447-25453.
2. Sprang, S.R. 1997. G proteins, effectors and GAPs: structure and mechanism. Curr. Opin. Struct. Biol. 7: 849-856.
3. Schenker, T. and Trueb, B. 1997. Assignment of the gene for a developmentally regulated GTP-binding protein (DRG2) to human chromosome bands 17p13→p12 by *in situ* hybridization. Cytogenet. Cell Genet. 79: 274-275.
4. Li, B. and Trueb, B. 2000. DRG represents a family of two closely related GTP-binding proteins. Biochim. Biophys. Acta 1491: 196-204.
5. Vlangos, C.N., Das, P., Patel, P.I. and Elsea, S.H. 2000. Assignment of developmentally regulated GTP-binding protein (DRG2) to human chromosome band 17p11.2 with somatic cell hybrids and localization to the Smith-Magenis syndrome critical interval. Cytogenet. Cell Genet. 88: 283-285.
6. Online Mendelian Inheritance in Man, OMIM™. 2001. Johns Hopkins University, Baltimore, MD. MIM Number: 602986. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
7. Bi, W., Yan, J., Stankiewicz, P., Park, S.S., Walz, K., Boerkoel, C.F., Potocki, L., Shaffer, L.G., Devriendt, K., Nowaczyk, M.J., Inoue, K. and Lupski, J.R. 2002. Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse. Genome Res. 12: 713-728.
8. Song, H., Kim, S.I., Ko, M.S., Kim, H.J., Heo, J.C., Lee, H.J., Lee, H.S., Han, I.S., Kwack, K. and Park, J.W. 2004. Overexpression of DRG2 increases G_2/M phase cells and decreases sensitivity to nocodazole-induced apoptosis. J. Biochem. 135: 331-335.
9. Bronberg, R., Ziembar, M., Drut, M. and Goldschmidt, E. 2008. Smith-Magenis syndrome: case report and review. Arch. Argent. Pediatr. 106: 143-146.

CHROMOSOMAL LOCATION

Genetic locus: DRG2 (human) mapping to 17p11.2; Drg2 (mouse) mapping to 11 B2.

SOURCE

DRG2 (L-13) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of DRG2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-164233 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

DRG2 (L-13) is recommended for detection of DRG2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with DRG1 or DRG11.

DRG2 (L-13) is also recommended for detection of DRG2 in additional species, including equine, canine, bovine and avian.

Suitable for use as control antibody for DRG2 siRNA (h): sc-93839, DRG2 siRNA (m): sc-143171, DRG2 shRNA Plasmid (h): sc-93839-SH, DRG2 shRNA Plasmid (m): sc-143171-SH, DRG2 shRNA (h) Lentiviral Particles: sc-93839-V and DRG2 shRNA (m) Lentiviral Particles: sc-143171-V.

Molecular Weight of DRG2: 41 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.